Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes

Cardiology Clinics

Volumn 23, Issue 2, 2005, Pages 119-138

  Jawa, Ali A ^a,b   Fonseca, Vivian A ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOHEXAMIDE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; NATEGLINIDE; POTASSIUM CHANNEL; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MEMBRANE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG CHOICE; DRUG POTENCY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART INFARCTION PREVENTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CLEARANCE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN;

EID: 13444302554     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2004.06.001     Document Type: Review

References (179)

1. W.B. Kannel, and D.L. McGee Diabetes and cardiovascular disease. The Framingham study JAMA 241 19 1979 2035 2038
2. S.M. Haffner Management of dyslipidemia in adults with diabetes Diabetes Care 21 1 1998 160 178
3. P.H. Stone, J.E. Muller, T. Hartwell, B.J. York, J.D. Rutherford, and C.B. Parker The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group J Am Coll Cardiol 14 1 1989 49 57
4. B. Stein, W.S. Weintraub, S.P. Gebhart, C.L. Cohen-Bernstein, R. Grosswald, and H.A. Liberman Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty Circulation 91 4 1995 979 989
5. K. Gu, C.C. Cowie, and M.I. Harris Diabetes and decline in heart disease mortality in US adults JAMA 281 14 1999 1291 1297
6. S. Lillioja, D.M. Mott, M. Spraul, R. Ferraro, J.E. Foley, and E. Ravussin Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians N Engl J Med 329 27 1993 1988 1992
7. E. Ferrannini Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects Endocr Rev 19 4 1998 477 490
8. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 9131 1998 837 853
9. D. Einhorn, M. Rendell, J. Rosenzweig, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group Clin Ther 22 12 2000 1395 1409
10. V. Fonseca, J. Rosenstock, R. Patwardhan, and A. Salzman Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial JAMA 283 13 2000 1695 1702
11. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 1998 854 865
12. K. Malmberg, L. Ryden, S. Efendic, J. Herlitz, P. Nicol, and A. Waldenstrom Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J Am Coll Cardiol 26 1 1995 57 65
13. J.D. Brunzell, and J.E. Hokanson Dyslipidemia of central obesity and insulin resistance Diabetes Care 22 Suppl 3 1999 C10 C13
14. H.N. Ginsberg, and L.S. Huang The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis J Cardiovasc Risk 7 5 2000 325 331
15. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) JAMA 285 19 2001 2486 2497
16. H.O. Steinberg, G. Paradisi, G. Hook, K. Crowder, J. Cronin, and A.D. Baron Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production Diabetes 49 7 2000 1231 1238
17. G.M. Reaven, H. Lithell, and L. Landsberg Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system N Engl J Med 334 6 1996 374 381
18. J.P. Despres, B. Lamarche, P. Mauriege, B. Cantin, G.R. Dagenais, and S. Moorjani Hyperinsulinemia as an independent risk factor for ischemic heart disease N Engl J Med 334 15 1996 952 957
19. F.M. Martens, F.L. Visseren, J. Lemay, E.J. de Koning, and T.J. Rabelink Metabolic and additional vascular effects of thiazolidinediones Drugs 62 10 2002 1463 1480
20. A.A. Parulkar, M.L. Pendergrass, R. Granda-Ayala, T.R. Lee, and V.A. Fonseca Nonhypoglycemic effects of thiazolidinediones Ann Intern Med 134 1 2001 61 71
21. K.L. Cohen, and S. Harris Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics Diabetes Care 10 5 1987 555 557
22. O.G. Kolterman, M.J. Prince, and J.M. Olefsky Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro Am J Med 74 1A 1983 82 101
23. M.G. Goldner, G.L. Knatterud, and T.E. Prout Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results JAMA 218 9 1971 1400 1410
24. C. Kilo, J.P. Miller, and J.R. Williamson The crux of the UGDP. Spurious results and biologically inappropriate data analysis Diabetologia 18 3 1980 179 185
25. E. Deutsch, M. Berger, W.G. Kussmaul, J.W. Hirshfeld Jr., H.C. Herrmann, and W.K. Laskey Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features Circulation 82 6 1990 2044 2051
26. B.R. Zimmerman Sulfonylureas Endocrinol Metab Clin North Am 26 3 1997 511 522
27. J.W. Doar, M.E. Thompson, C.E. Wilde, and P.F. Sewell Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus BMJ 1 6008 1976 498 500
28. D.C. Simonson, E. Ferrannini, S. Bevilacqua, D. Smith, E. Barrett, and R. Carlson Mechanism of improvement in glucose metabolism after chronic glyburide therapy Diabetes 33 9 1984 838 845
29. K.N. Garratt, P.A. Brady, N.L. Hassinger, D.E. Grill, A. Terzic, and D.R. Holmes Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 33 1 1999 119 124
30. R.R. Henry Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention Am J Med 105 1A 1998 20S 26S
31. K.N. Garratt, P.A. Brady, N.L. Hassinger, D.E. Grill, A. Terzic, and D.R. Holmes Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 33 1 1999 119 124
32. R.A. Kloner, and D. Yellon Does ischemic preconditioning occur in patients? [abstract] J Am Coll Cardiol 24 4 1994 1133 1142
33. C.E. Murry, R.B. Jennings, and K.A. Reimer Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74 5 1986 1124 1136
34. G.J. Gross, and J.A. Auchampach Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs Circ Res 70 2 1992 223 233
35. G.J. Grover, P.G. Sleph, and S. Dzwonczyk Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors Circulation 86 4 1992 1310 1316
36. + channels protect the myocardium against ischemia/reperfusion damage Circ Res 69 3 1991 571 581
37. T.M. Lee, S.F. Su, C.C. Tsai, Y.T. Lee, and C.H. Tsai Cardioprotective effects of 17 beta-estradiol produced by activation ofmitochondrial ATP-sensitive K(+)Channels in canine hearts J Mol Cell Cardiol 32 7 2000 1147 1158
38. + channel blocker Circulation 90 2 1994 700 705
39. Y.Z. Qian, J.E. Levasseur, K. Yoshida, and R.C. Kukreja KATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide Am J Physiol 271 1 Pt 2 1996 H23 H28
40. T. Sato, N. Sasaki, B. O'Rourke, and E. Marban Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels J Am Coll Cardiol 35 2 2000 514 518
41. R.A. Fenton, E.W. Dickson, T.E. Meyer, and J.G. Dobson Jr. Aging reduces the cardioprotective effect of ischemic preconditioning in the rat heart J Mol Cell Cardiol 32 7 2000 1371 1375
42. P. Abete, N. Ferrara, A. Cioppa, P. Ferrara, S. Bianco, and C. Calabrese Preconditioning does not prevent postischemic dysfunction in aging heart J Am Coll Cardiol 27 7 1996 1777 1786
43. P.G. Burns, I.B. Krunkenkamp, C.A. Calderone, R.J. Kirvaitis, G.R. Gaudette, and S. Levitsky Is the preconditioning response conserved in senescent myocardium? Ann Thorac Surg 61 3 1996 925 929
44. B. O'Rourke Myocardial K(ATP) channels in preconditioning Circ Res 87 10 2000 845 855
45. + channel-opening drugs Am J Physiol 269 3 Pt 1 1995 C525 C545
46. L. Aguilar-Bryan, J.P. Clement, G. Gonzalez, K. Kunjilwar, A. Babenko, and J. Bryan Toward understanding the assembly and structure of KATP channels Physiol Rev 78 1 1998 227 245
47. M. Lazdunski Ion channel effects of antidiabetic sulfonylureas Horm Metab Res 28 9 1996 488 495
48. W. Kramer, G. Muller, and K. Geisen Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells Horm Metab Res 28 9 1996 464 468
49. F.M. Ashcroft Mechanisms of the glycaemic effects of sulfonylureas Horm Metab Res 28 9 1996 456 463
50. M.M. Mocanu, H.L. Maddock, G.F. Baxter, C.L. Lawrence, N.B. Standen, and D.M. Yellon Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide Circulation 103 25 2001 3111 3116
51. K. Geisen, A. Vegh, E. Krause, and J.G. Papp Cardiovascular effects of conventional sulfonylureas and glimepiride Horm Metab Res 28 9 1996 496 507
52. J.C. Cleveland Jr., D.R. Meldrum, B.S. Cain, A. Banerjee, and A.H. Harken Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited Circulation 96 1 1997 29 32
53. H. Klepzig, G. Kober, C. Matter, H. Luus, H. Schneider, and K.H. Boedeker Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide Eur Heart J 20 6 1999 439 446
54. A.P. Babenko, and J. Bryan A conserved inhibitory and differential stimulatory action of nucleotides on K(IR)6.0/SUR complexes is essential for excitation-metabolism coupling by K(ATP) channels J Biol Chem 276 52 2001 49083 49092
55. G. Muller, D. Hartz, J. Punter, R. Okonomopulos, and W. Kramer Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics Biochim Biophys Acta 1191 2 1994 267 277
56. T.M. Lee, and T.F. Chou Impairment of myocardial protection in type 2 diabetic patients J Clin Endocrinol Metab 88 2 2003 531 537
57. A. Tosaki, P. Szerdahelyi, R.M. Engelman, and D.K. Das Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther 267 3 1993 1355 1362
58. A. Holstein, A. Plaschke, and E.H. Egberts Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev 17 6 2001 467 473
59. C. Desouza, H. Salazar, B. Cheong, J. Murgo, and V. Fonseca Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring Diabetes Care 26 5 2003 1485 1489
60. R. Perfetti, and A. Ahmad Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin Trends Endocrinol Metab 11 6 2000 218 223
61. Y. Hirschberg, A.H. Karara, A.O. Pietri, and J.F. McLeod Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin Diabetes Care 23 3 2000 349 353
62. M. Nattrass, and T. Lauritzen Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 24 Suppl 3 2000 S21 S31
63. L. Keilson, S. Mather, Y.H. Walter, S. Subramanian, and J.F. McLeod Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 85 3 2000 1081 1086
64. R.B. Goldberg, D. Einhorn, C.P. Lucas, M.S. Rendell, P. Damsbo, and W.C. Huang A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes Diabetes Care 21 11 1998 1897 1903
65. L. Jovanovic, G. Dailey III, W.C. Huang, P. Strange, and B.J. Goldstein Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study J Clin Pharmacol 40 1 2000 49 57
66. M. Hanefeld, K.P. Bouter, S. Dickinson, and C. Guitard Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia Diabetes Care 23 2 2000 202 207
67. B.H. Wolffenbuttel, and R. Landgraf A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group Diabetes Care 22 3 1999 463 467
68. R. Landgraf, H.J. Bilo, and P.G. Muller A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas Eur J Clin Pharmacol 55 3 1999 165 171
69. T. Marbury, W.C. Huang, P. Strange, and H. Lebovitz Repaglinide versus glyburide: a one-year comparison trial Diabetes Res Clin Pract 43 3 1999 155 166
70. R. Moses, R. Slobodniuk, S. Boyages, S. Colagiuri, W. Kidson, and J. Carter Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 22 1 1999 119 124
71. P. Raskin, L. Jovanovic, S. Berger, S. Schwartz, V. Woo, and R. Ratner Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes Diabetes Care 23 7 2000 979 983
72. E.S. Horton, C. Clinkingbeard, M. Gatlin, J. Foley, S. Mallows, and S. Shen Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes Diabetes Care 23 11 2000 1660 1665
73. C.J. Bailey, and R.C. Turner Metformin N Engl J Med 334 9 1996 574 579
74. G.B. Kolata The phenformin ban: is the drug an imminent hazard? Science 203 4385 1979 1094 1096
75. K. Johansen Efficacy of metformin in the treatment of NIDDM. Meta-analysis Diabetes Care 22 1 1999 33 37
76. M. Stumvoll, N. Nurjhan, G. Perriello, G. Dailey, and J.E. Gerich Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N Engl J Med 333 9 1995 550 554
77. D. Kirpichnikov, S.I. McFarlane, and J.R. Sowers Metformin: an update Ann Intern Med 137 1 2002 25 33
78. A.C. Robinson, J. Burke, S. Robinson, D.G. Johnston, and R.S. Elkeles The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control Diabetes Care 21 5 1998 701 705
79. E.J. Murphy, T.J. Davern, A.O. Shakil, L. Shick, U. Masharani, and H. Chow Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group Dig Dis Sci 45 3 2000 549 553
80. A.J. Scheen, and P.J. Lefebvre Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes Diabetes Care 22 9 1999 1568 1577
81. P. Raskin, E.B. Rappaport, S.T. Cole, Y. Yan, R. Patwardhan, and M.I. Freed Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes Diabetologia 43 3 2000 278 284
82. M.N. Ghazzi, J.E. Perez, T.K. Antonucci, J.H. Driscoll, S.M. Huang, and B.W. Faja Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group Diabetes 46 3 1997 433 439
83. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N Engl J Med 331 18 1994 1188 1193
84. R.L. Prigeon, S.E. Kahn, and D. Porte Jr. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus J Clin Endocrinol Metab 83 3 1998 819 823
85. Y. Yamasaki, R. Kawamori, T. Wasada, A. Sato, Y. Omori, and H. Eguchi Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan Tohoku J Exp Med 183 3 1997 173 183
86. A. Bakst, S. Schwartz, and J.S. Fischer Avandia worldwide awareness registry: improved metabolic control with initiation of rosiglitazone in a diabetes clinic setting Diabetes 50 Suppl 2 2001 6 26 A430
87. A.J. Wagstaff, and K.L. Goa Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus Drugs 62 12 2002 1805 1837
88. S.E. Inzucchi, D.G. Maggs, G.R. Spollett, S.L. Page, F.S. Rife, and V. Walton Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 338 13 1998 867 872
89. S. Kersten, B. Desvergne, and W. Wahli Roles of PPARs in health and disease Nature 405 6785 2000 421 424
90. J.M. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists J Clin Invest 106 4 2000 467 472
91. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, and K. Umesono The nuclear receptor superfamily: the second decade Cell 83 6 1995 835 839
92. E. Hu, P. Tontonoz, and B.M. Spiegelman Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha Proc Natl Acad Sci USA 92 21 1995 9856 9860
93. T. Lemberger, O. Braissant, C. Juge-Aubry, H. Keller, R. Saladin, and B. Staels PPAR tissue distribution and interactions with other hormone-signaling pathways Ann N Y Acad Sci 804 1996 231 251
94. S.A. Kliewer, B.M. Forman, B. Blumberg, E.S. Ong, U. Borgmeyer, and D.J. Mangelsdorf Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proc Natl Acad Sci USA 91 15 1994 7355 7359
95. M. Ricote, J. Huang, L. Fajas, A. Li, J. Welch, and J. Najib Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein Proc Natl Acad Sci USA 95 13 1998 7614 7619
96. N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro Am J Pathol 153 1 1998 17 23
97. G. Viberti, S.E. Kahn, D.A. Greene, W.H. Herman, B. Zinman, and R.R. Holman A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes Diabetes Care 25 10 2002 1737 1743
98. M.I. Freed, R. Ratner, S.M. Marcovina, M.M. Kreider, N. Biswas, and B.R. Cohen Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus Am J Cardiol 90 9 2002 947 952
99. S. Rosenblatt, B. Miskin, N.B. Glazer, M.J. Prince, and K.E. Robertson The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus Coron Artery Dis 12 5 2001 413 423
100. S.L. Suter, J.J. Nolan, P. Wallace, B. Gumbiner, and J.M. Olefsky Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 15 2 1992 193 203
101. Troglitazone Study Group The metabolic effects of troglitazone in non-insulin dependent diabetes (NIDDM) [abstract] Diabetes 46 Suppl 1 1997 149A
102. M.J. Prince, A.J. Zagar, and K.E. Robertson Effect of pioglitazone on HDL-C, a cardiovascular risk factor in type 2 diabetes [abstract] Diabetes 50 Suppl 2 2001 A128
103. V. Brown Detection and management of lipid disorders in diabetes Diabetes Care Suppl 1 1996 S96 S102
104. H.N. Ginsberg Insulin resistance and cardiovascular disease J Clin Invest 106 4 2000 453 458
105. M.A. Austin Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond Am J Epidemiol 129 2 1989 249 259
106. A. Chait, R.L. Brazg, D.L. Tribble, and R.M. Krauss Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B Am J Med 94 4 1993 350 356
107. J. de Graaf, H.L. Hak-Lemmers, M.P. Hectors, P.N. Demacker, J.C. Hendriks, and A.F. Stalenhoef Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects Arterioscler Thromb 11 2 1991 298 306
108. H.E. Lebovitz, and M.A. Banerji Insulin resistance and its treatment by thiazolidinediones Recent Prog Horm Res 56 2001 265 294
109. C.J. Tack, P. Smits, P.N. Demacker, and A.F. Stalenhoef Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects Diabetes Care 21 5 1998 796 799
110. K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, and M.W. Baumstark Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study Diabetes Care 26 9 2003 2588 2594
111. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma Cell 93 2 1998 229 240
112. G. Chinetti, S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, and I.P. Torra PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat Med 7 1 2001 53 58
113. P. Tontonoz, L. Nagy, J.G. Alvarez, V.A. Thomazy, and R.M. Evans PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 2 1998 241 252
114. A. Raji, E.W. Seely, S.A. Bekins, G.H. Williams, and D.C. Simonson Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients Diabetes Care 26 1 2003 172 178
115. T. Ogihara, H. Rakugi, H. Ikegami, H. Mikami, and K. Masuo Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives Am J Hypertens 8 3 1995 316 320
116. G. Bakris, G. Viberti, W.M. Weston, M. Heise, L.E. Porter, and M.I. Freed Rosiglitazone reduces urinary albumin excretion in type II diabetes J Hum Hypertens 17 1 2003 7 12
117. Scherbaun W, Göke B. For the German Pioglitazone Study Group. Pioglitazone reduces blood pressure in patients with type 2 diabetes mellitus diabetes. 2001;50:A462.
118. C.J. Tack, M.K. Ong, J.A. Lutterman, and P. Smits Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone Diabetologia 41 5 1998 569 576
119. + currents and not endothelial nitric oxide production Diabetes 46 4 1997 659 664
120. E. Morikang, S.C. Benson, T.W. Kurtz, and H.A. Pershadsingh Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes Am J Hypertens 10 4 Pt 1 1997 440 446
121. H.Y. Zhang, S.R. Reddy, and T.A. Kotchen Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity Hypertension 24 1 1994 106 110
122. T.A. Buchanan, W.P. Meehan, Y.Y. Jeng, D. Yang, T.M. Chan, and J.L. Nadler Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect J Clin Invest 96 1 1995 354 360
123. D.J. Blackman, J.A. Morris-Thurgood, J.J. Atherton, G.R. Ellis, R.A. Anderson, and J.R. Cockcroft Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans Circulation 101 2 2000 165 170
124. J. Tooke The association between insulin resistance and endotheliopathy Diabetes Obes Metab 1 Suppl 1 1999 S17 S22
125. J.A. Vita, B. Frei, M. Holbrook, N. Gokce, C. Leaf, and J.F. Keaney Jr. L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease J Clin Invest 101 6 1998 1408 1414
126. P. Dandona, A. Aljada, and P. Mohanty The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm Diabetologia 45 6 2002 924 930
127. R. Avena, M.E. Mitchell, E.S. Nylen, K.M. Curry, and A.N. Sidawy Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes J Vasc Surg 28 6 1998 1024 1031
128. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP1): evidence of a potent antiinflammatory effect [abstract] Diabetes 50 suppl 2 2001 A68
129. M.Y. Ohta, Y. Nagai, T. Takamura, E. Nohara, and K. Kobayashi Inhibitory effect of troglitazone on TNF-alpha-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells Diabetes Res Clin Pract 48 3 2000 171 176
130. L. Cominacini, U. Garbin, A.F. Pasini, A. Davoli, M. Campagnola, and A. Rigoni The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity Cell Adhes Commun 7 3 1999 223 231
131. T. Yoshimoto, M. Naruse, H. Shizume, K. Naruse, A. Tanabe, and M. Tanaka Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy Atherosclerosis 145 2 1999 333 340
132. K. Kato, H. Satoh, Y. Endo, D. Yamada, S. Midorikawa, and W. Sato Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function Biochem Biophys Res Commun 258 2 1999 431 435
133. H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, and E. Assian Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese J Clin Endocrinol Metab 86 3 2001 1306 1312
134. N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R.E. Buckingham, B. Staels, and A. Bril Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury Diabetes 51 5 2002 1507 1514
135. T.L. Yue Tl, J. Chen, W. Bao, P.K. Narayanan, A. Bril, and W. Jiang In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone Circulation 104 21 2001 2588 2594
136. D.H. O'Leary, J.F. Polak, R.A. Kronmal, T.A. Manolio, G.L. Burke, and S.K. Wolfson Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group N Engl J Med 340 1 1999 14 22
137. J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 83 5 1998 1818 1820
138. H. Koshiyama, D. Shimono, N. Kuwamura, J. Minamikawa, and Y. Nakamura Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 86 7 2001 3452 3456
139. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 6662 1998 82 86
140. D.A. Ehrmann, D.J. Schneider, B.E. Sobel, M.K. Cavaghan, J. Imperial, and R.L. Rosenfield Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 7 1997 2108 2116
141. V.A. Fonseca, J. Diez, and D.B. McNamara Decreasing restenosis following angioplasty: the potential of peroxisome proliferator-activated receptor gamma agonists Diabetes Care 27 11 2004 2764 2766
142. W.S. Weintraub, B. Stein, A. Kosinski, J.S. Douglas Jr., Z.M. Ghazzal, E.L. Jones, D.C. Morris, R.A. Guyton, J.M. Craver, and S.B. King III Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease J Am Coll Cardiol 31 1998 10 19
143. D. Choi, S.K. Kim, and S.H. Choi Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes Diabetes Care 27 2004 2654 2660
144. T. Takagi, A. Yamamuro, K. Tamita, and K. Yamabe Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study Am Heart J 146 2 2003 E5
145. M.B. Davidson Clinical implications of insulin resistance syndromes Am J Med 99 4 1995 420 426
146. D.K. Nagi, and J.S. Yudkin Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups Diabetes Care 16 4 1993 621 629
147. A. Melidonis, A. Stefanidis, S. Tournis, S. Manoussakis, S. Handanis, and M. Zairis The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients Clin Cardiol 23 3 2000 160 164
148. B.E. Sobel Coronary artery disease and fibrinolysis: from the blood to the vessel wall Thromb Haemost 82 Suppl 1 1999 8 13
149. V.A. Fonseca, T. Reynolds, D. Hemphill, C. Randolph, J. Wall, and T.R. Valiquet Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus J Diabetes Complications 12 4 1998 181 186
150. Y.T. Kruszynska, J.G. Yu, J.M. Olefsky, and B.E. Sobel Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects Diabetes 49 4 2000 633 639
151. T.K. Nordt, K. Peter, C. Bode, and B.E. Sobel Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells J Clin Endocrinol Metab 85 4 2000 1563 1568
152. M. Freed, D. Fuell, L. Menci, M. Heise, and M. Heise Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes [abstract] Diabetologia 43 Suppl 1 2000 A267
153. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 20 2002 1557 1565
154. D.L. Fuell, M.I. Freed, A.S. Greenberg, S. Haffner, and H. Chen The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with Type 2 diabetes [abstract] Diabetes 50 Suppl 2 2001 A435
155. S.M. Haffner, A.S. Greenberg, W.M. Weston, H. Chen, K. Williams, and M.I. Freed Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 6 2002 679 684
156. P. Mohanty, A. Aljada, and H. Ghanim Evidence for a potent antiinflammatory effect of rosiglitazone J Clin Endocrinol Metab 89 6 2004 2728 2735
157. E. Imano, T. Kanda, Y. Nakatani, T. Nishida, K. Arai, and M. Motomura Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy Diabetes Care 21 12 1998 2135 2139
158. M.B. Mattock, N.J. Morrish, G. Viberti, H. Keen, A.P. Fitzgerald, and G. Jackson Prospective study of microalbuminuria as predictor of mortality in NIDDM Diabetes 41 6 1992 736 741
159. H.E. Lebovitz, J.F. Dole, R. Patwardhan, E.B. Rappaport, and M.I. Freed Rosiglitazone monotherapy is effective in patients with type 2 diabetes J Clin Endocrinol Metab 86 1 2001 280 288
160. S.B. Nicholas, Y. Kawano, S. Wakino, A.R. Collins, and W.A. Hsueh Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells Hypertension 37 2 Part 2 2001 722 727
161. V. Fonseca, H.L. Foyt, K. Shen, and R. Whitcomb Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients Diabetes Care 23 3 2000 354 359
162. Y. Mori, Y. Murakawa, K. Okada, H. Horikoshi, J. Yokoyama, and N. Tajima Effect of troglitazone on body fat distribution in type 2 diabetic patients Diabetes Care 22 6 1999 908 912
163. J. Patel, R.J. Anderson, and E.B. Rappaport Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study Diabetes Obes Metab 1 3 1999 165 172
164. B.M. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione
165. S. Akazawa, F. Sun, M. Ito, E. Kawasaki, and K. Eguchi Efficacy of troglitazone on body fat distribution in type 2 diabetes Diabetes Care 23 8 2000 1067 1071
166. I.E. Kelly, T.S. Han, K. Walsh, and M.E. Lean Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes Diabetes Care 22 2 1999 288 293
167. T. Nakamura, T. Funahashi, S. Yamashita, M. Nishida, Y. Nishida, and M. Takahashi Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial Diabetes Res Clin Pract 54 3 2001 181 190
168. D.G. Carey, A.B. Jenkins, L.V. Campbell, J. Freund, and D.J. Chisholm Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM Diabetes 45 5 1996 633 638
169. A.H. Kissebah, and G.R. Krakower Regional adiposity and morbidity Physiol Rev 74 4 1994 761 811
170. D.G. Carey, G.J. Cowin, G.J. Galloway, N.P. Jones, J.C. Richards, and N. Biswas Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients Obes Res 10 10 2002 1008 1015
171. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, and K. Cusi Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 6 2002 2784 2791
172. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators Protocol for the Bypass Angioplasty Revascularization Investigation Circulation 84 Suppl V 1991 V1 V27
173. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators N Engl J Med 335 4 1996 217 225
174. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status J Am Coll Cardiol 35 5 2000 1122 1129
175. BARI2D trial. Available at http://www.bari2D.org.
176. G. Erle, S. Lovise, C. Stocchiero, L. Lora, A. Coppini, and P. Marchetti A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients Acta Diabetol 36 1-2 1999 61 65
177. R.A. DeFronzo, and A.M. Goodman Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group N Engl J Med 333 9 1995 541 549
178. E.S. Horton, F. Whitehouse, M.N. Ghazzi, T.C. Venable, and R.W. Whitcomb Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group Diabetes Care 21 9 1998 1462 1469
179. B.H. Wolffenbuttel, R. Gomis, S. Squatrito, N.P. Jones, and R.N. Patwardhan Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients Diabet Med 17 1 2000 40 47